✦ LIBER ✦

Prognostic factors in multiple myeloma

✍ Scribed by Raymond Alexanian; Stanley Balcerzak; John D. Bonnet; Edmund A. Gehan; Arthur Haut; James S. Hewlett; Raymond W. Monto

Book ID: 102665328
Publisher: John Wiley and Sons
Year: 1975
Tongue: English
Weight: 751 KB
Volume: 36
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(197510)36:4<1192::aid-cncr2820360403>3.0.co;2-i

No coin nor oath required. For personal study only.

✦ Synopsis

Includes 17 patients with untyped light chains.

📜 SIMILAR VOLUMES

Prognostic factors in multiple myeloma

✍ Robert A. Kyle 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 422 KB

Prognostic factors in multiple myeloma

✍ Nehemiah C. Cherng; Nabih R. Asal; Elisa T. Lee; J. Philip Kuebler; Dilip Solank 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 682 KB

Prognostic factors in multiple myeloma:

Prognostic factors in multiple myeloma: role of ?2-microglobulin and thymidine kinase

✍ Diem, H. ;Fateh-Moghadam, A. ;Lamerz, R. 📂 Article 📅 1993 🏛 Springer-Verlag 🌐 English ⚖ 722 KB

Serum [32-microglobulin , serum thymidine kinase, and commonly used prognostic parameters were investigated for their prognostic value in a well-defined group of patients with multiple myeloma (n = 207). Multivariate analysis showed hemoglobin to be the parameter of strongest prognostic value. Only

Prognostic significance of the serum pho

Prognostic significance of the serum phosphorus level and its relationship with other prognostic factors in multiple myeloma

✍ Masanori Umeda; Shinya Okuda; Haruka Izumi; Daisuke Nagase; Yoshinori Fujimoto; 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 124 KB

O23 Proliferation and apoptosis in multi

O23 Proliferation and apoptosis in multiple myeloma prognostic factors or kinetic parameters?

✍ J. Minarik; V. Scudla; M. Ordeltova; J. Bacovsky; M. Zemanova; T. Pika 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 47 KB

note, in 19 patients, remission achieved by bortezomib-based therapy was consolidated by high-dose therapy followed by autologous stem cell transplantation. With a median follow-up time of 11 months (1 27 months), the median progression-free survival of our entire patient population is 13.8 month, w

Prognostic factors in elderly multiple m

Prognostic factors in elderly multiple myeloma patients aged 65 years or older: Comparison with nonelderly patients with multiple myeloma

✍ Masanori Umeda; Shinya Okuda; Haruka Izumi; Yasuyuki Sugasawa; Chiaki Arai; Kazu 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB